Anahita Rabiee, MD, MHS
Instructor of Medicine (Digestive Diseases)Cards
About
Research
Publications
2024
Safety of naltrexone in patients with cirrhosis
Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Reports 2024, 6: 101095. PMID: 38961852, PMCID: PMC11220533, DOI: 10.1016/j.jhepr.2024.101095.Peer-Reviewed Original ResearchDrug-induced liver injuryRoussel Uclaf Causality Assessment MethodAlcohol use disorderInitiation of naltrexoneSafety of naltrexoneUse disorderRetrospective studyDevelopment of drug-induced liver injuryRoussel Uclaf Causality Assessment Method scoreLiver injuryLiver diseaseRetrospective study of patientsTreatment of alcohol use disordersTreat alcohol use disorderLiver enzyme elevationAlcohol-related cirrhosisCohort of patientsAlkaline phosphatase elevationDiagnosis of cirrhosisStudy of patientsAssociated with developmentCausality Assessment MethodPrescribed naltrexoneDecompensated cirrhosisEnzyme elevationKeep beta-blocking and carry on!
Rabiee A, Rabiee A. Keep beta-blocking and carry on! Clinical Liver Disease 2024, 23: e0114. PMID: 38304323, PMCID: PMC10833629, DOI: 10.1097/cld.0000000000000114.Peer-Reviewed Original Research
2023
Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension
Rabiee A, Cornman-Homonoff J, Kunstman J, Garcia-Tsao G, Taddei T. Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension. Current Hepatology Reports 2023, 22: 269-275. DOI: 10.1007/s11901-023-00617-4.Peer-Reviewed Original ResearchPortal hypertensionInterventional radiologyNon-cirrhotic portal hypertensionPorto-sinusoidal vascular diseaseHepatic sinusoidal obstruction syndromeAbsence of cirrhosisPortal vein thrombosisSinusoidal obstruction syndromeBudd-Chiari syndromeSurgical treatment optionsHepatic vascular anatomyObstruction syndromeVein thrombosisSurgical treatmentTreatment optionsVascular diseaseImproved outcomesTherapeutic evaluationVascular anatomyHeterogenous groupHypertensionSyndromeDisordersOutcomesTreatmentBrief overview of immunosuppression and its side effects after liver transplantation
Rabiee A, Girone G, Davis J. Brief overview of immunosuppression and its side effects after liver transplantation. Clinical Liver Disease 2023, 21: 160-164. PMID: 37937047, PMCID: PMC10627593, DOI: 10.1097/cld.0000000000000035.Peer-Reviewed Original ResearchMedications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis
Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan D. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatology Communications 2023, 7: e0093. PMID: 36972386, PMCID: PMC10043587, DOI: 10.1097/hc9.0000000000000093.Peer-Reviewed Original ResearchConceptsAlcohol-associated cirrhosisAlcohol use disorderUse disordersCause mortalityImproved survivalPropensity scoreInpatient diagnosis codesRetrospective cohort studyCox regression analysisActive alcohol useCirrhosis decompensationCohort studyConcurrent diagnosisLiver diseasePotential confoundersDiagnosis codesVeteran outcomesCirrhosis diagnosisStrong negative predictorCirrhosisPatientsHazardous drinkingAlcohol use behaviorsCosts AssociatedAlcohol use
2022
Simplifying the Diagnosis and Treatment of Hepatitis B Infection: One Step for Addressing Deficits in the Care Cascade, One Leap for Elimination
Rabiee A, Lim J. Simplifying the Diagnosis and Treatment of Hepatitis B Infection: One Step for Addressing Deficits in the Care Cascade, One Leap for Elimination. Gastro Hep Advances 2022, 2: 277-278. PMID: 39132614, PMCID: PMC11307652, DOI: 10.1016/j.gastha.2022.12.002.Commentaries, Editorials and LettersNoninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
Rabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia‐Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model. Hepatology Communications 2022, 6: 3324-3334. PMID: 36214066, PMCID: PMC9701481, DOI: 10.1002/hep4.2091.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientSignificant portal hypertensionTransient elastographyNASH cirrhosisPortal hypertensionFibrosis-4 indexPresence of CSPHVenous pressure gradientNonalcoholic steatohepatitis cirrhosisBody mass indexLiver stiffness measurementGood calibrationCompensated cirrhosisFIB-4Mass indexPlatelet countValidation cohortNoninvasive predictorTraining cohortBaseline riskLaboratory valuesCirrhosisHigh riskSeparate cohortNoninvasive surrogateNonselective Beta‐Blockers in Portal Hypertension: Why, When, and How?
Rabiee A, Garcia‐Tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease 2022, 19: 118-123. PMID: 35355838, PMCID: PMC8958249, DOI: 10.1002/cld.1182.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis
Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.Peer-Reviewed Original ResearchQuality of lifeMindfulness-based stress reductionInflammatory cytokine levelsDisease activityCytokine levelsAutoimmune hepatitisAlanine aminotransferaseAdult patientsTRIAL REGISTRATIONPeripheral blood cytokine levelsScore improvementMBSR programPilot studyBlood cytokine levelsSerum alanine aminotransferaseClinical trial registrationSignificant dose reductionPerceived stressExploratory pilot studyALT levelsSteroid requirementsStress reductionCytokine mediatorsALT reductionMedication needs
2021
Changes in Ascitic Fluid Polymorphonuclear Cell Count After Antibiotics Are Associated With Mortality in Spontaneous Bacterial Peritonitis
Saffo S, To UK, Santoiemma PP, Laurito M, Haque L, Rabiee A, Verna EC, Angarone MP, Garcia-Tsao G. Changes in Ascitic Fluid Polymorphonuclear Cell Count After Antibiotics Are Associated With Mortality in Spontaneous Bacterial Peritonitis. Clinical Gastroenterology And Hepatology 2021, 20: e1201-e1204. PMID: 34273564, PMCID: PMC11090177, DOI: 10.1016/j.cgh.2021.07.019.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- August 02, 2023
Highlighting Gender-based Differences in Alcohol-associated Hepatitis
- January 16, 2023
Yale School of Medicine community stand in solidarity with Iranian healthcare workers in poignant demonstration
- January 11, 2023
Discoveries & Impact (January 2023)
- November 08, 2022
Zan, Zendegi, Azadi: Iranian Protest Stories Shared at Yale School of Medicine